Frontlight ResearchEarly access
WithdrawnPhase 2
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Key facts
- Who runs it
- Inova Health Care Services
- Where
- Falls Church, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 19 Sept 2025
- Ended
- 19 Sept 2025
- Type of study
- Interventional
- Treatments tested
- Biweekly 5-FLUOROURACIL (5-FU)
- Biweekly Modified FOLFOX6
- Biweekly FOLFIRI
- mFOLFOXIRI
- Record updated
- 11 February 2026
- Why it stopped
- Principal Investigator has left Inova
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Males or females at least 18 years of age
- Histologically confirmed metastatic colorectal cancer eligible for treatment with 5-FU
- No prior therapy for metastatic disease. If adjuvant 5-FU or FOLFOX was administered, the last dose must have been at least 6 months prior to the diagnosis of metastatic disease
- Adequate organ function
- Eastern Cooperative Oncology Group (ECOG) status less than or equal to 2
- Life expectancy > 3 months
Who cannot take part
- Untreated brain metastasis. Treated brain metastases are allowed as long as symptoms have resolved off of steroids
- At least 4 weeks from any prior surgery or 2 weeks from radiation treatments
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
Where in United States
- Inova Health Care ServiceFalls Church, United States
About the trial
What the trial wants to find out
The purpose of this research is to see if adjusting the dose of 5-fluorouracil based on its concentration in your blood will improve the treatment of your metastatic colon cancer.
The group in the trial
- Chemotherapy with 5-FU/Leucovorin (LV) alone, with oxaliplatin or irinotecan or bothTreatment being tested
Plasma specimens will be collected for the measurement of plasma 5-FU level from patients receiving 5-FU/LV alone, with oxaliplatin (mFOLFOX6) or irinotecan (FOLFIRI), or both (mFOLFOXIRI) chemotherapy. 5-FU doses will be modified based on the assay results.
Treatment: Biweekly 5-FLUOROURACIL (5-FU), Biweekly Modified FOLFOX6, Biweekly FOLFIRI, and mFOLFOXIRI
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study of Pharmacokinetically (PK) Dose Adjusted 5-Fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
- Record updated
- 11 February 2026